TEMIRI

DRUG2 trials

Sponsors

Italian Sarcoma Group, Institut Curie

Conditions

Ewing Sarcoma Family of TumorsEwing's Sarcoma (ES)

Phase 2

Protocol for the Treatment of Metastatic Ewing Sarcoma

CompletedNCT02727387

Italian Sarcoma GroupEwing's Sarcoma (ES)

Start: 2009-06-01End: 2022-04-29Updated: 2022-09-19

First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)

CompletedNCT03011528

Institut CurieEwing Sarcoma Family of Tumors

Start: 2016-12-31End: 2023-11-30Updated: 2025-11-21

Related Papers

Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial.

2025-11-17

Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial

Universität Zürich, ZORA2025-11-17

Role of <sup>18</sup>F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?

2024-10-082 citations

Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study.

Journal of Clinical Oncology2020-05-205 citations

Activity of front-line window therapy with temozolomide plus irinotecan in patients with primary multifocal Ewing sarcoma: ISG/AIEOP EW-2 protocol.

Journal of Clinical Oncology2020-05-20